Compare LWAY & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWAY | LCTX |
|---|---|---|
| Founded | 1986 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.2M | 366.2M |
| IPO Year | 1987 | N/A |
| Metric | LWAY | LCTX |
|---|---|---|
| Price | $22.11 | $1.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $35.00 | $4.67 |
| AVG Volume (30 Days) | 49.7K | ★ 1.2M |
| Earning Date | 03-13-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $204,069,000.00 | $10,816,000.00 |
| Revenue This Year | $15.23 | $6.32 |
| Revenue Next Year | $13.72 | $124.49 |
| P/E Ratio | $29.61 | ★ N/A |
| Revenue Growth | 12.14 | ★ 24.05 |
| 52 Week Low | $19.50 | $0.37 |
| 52 Week High | $34.20 | $2.09 |
| Indicator | LWAY | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 51.23 |
| Support Level | $21.25 | $1.68 |
| Resistance Level | $22.50 | $1.90 |
| Average True Range (ATR) | 0.64 | 0.11 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 40.61 | 56.67 |
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.